Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2 Receptor Derived from the Natural Product Cannabidiol
Gemma Navarro, Ángel González, Adrià Sánchez-Morales, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 9354-9364
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling
Gemma Navarro, Marc Gómez‐Autet, Paula Morales, et al.
Pharmacological Research (2024) Vol. 208, pp. 107363-107363
Open Access | Times Cited: 17
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 975-975
Open Access | Times Cited: 45
Chiral Recognition of CIAC001 Isomers in Regulating Pyruvate Kinase M2 and Mitigating Neuroinflammation
Sha Jin, Xue Wang, Xin Zhou, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117262-117262
Closed Access | Times Cited: 1
Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors
Iu Raïch, Rafael Rivas‐Santisteban, Alejandro Lillo, et al.
Pharmacological Research (2021) Vol. 174, pp. 105970-105970
Open Access | Times Cited: 30
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands
Francesca Gado, Rebecca Ferrisi, Beatrice Polini, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 14, pp. 9918-9938
Open Access | Times Cited: 22
In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators
Jiayi Yuan, Chen Jiang, Junmei Wang, et al.
Molecules (2022) Vol. 27, Iss. 2, pp. 453-453
Open Access | Times Cited: 21
Identification of a Cannabinoid Receptor 2 Allosteric Site Using Computational Modeling and Pharmacological Analysis
Zara Farooq, Pietro Delre, Stylianos Iliadis, et al.
ACS Pharmacology & Translational Science (2025)
Open Access
Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (-) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives
Santiago Rodríguez-Carreiro, María Gómez‐Cañas, Francesca Lubrini, et al.
European Journal of Medicinal Chemistry Reports (2025), pp. 100262-100262
Open Access
Endocannabinoid signaling in the central nervous system
César E. Martinez Ramirez, Gonzalo Ruiz‐Pérez, Todd M. Stollenwerk, et al.
Glia (2022) Vol. 71, Iss. 1, pp. 5-35
Open Access | Times Cited: 18
Discovery of a CB2 and 5-HT1A receptor dual agonist for the treatment of depression and anxiety
Wenjiao Yang, Xudong Gong, Haiguo Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116048-116048
Closed Access | Times Cited: 9
Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation
Jiayi Yuan, Bo Ram Yang, Guanyu Hou, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103615-103615
Open Access | Times Cited: 8
Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs
Rafael Franco, Gemma Navarro
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
The Leu/Val6.51 Side Chain of Cannabinoid Receptors Regulates the Binding Mode of the Alkyl Chain of Δ9-Tetrahydrocannabinol
Claudia Llinás del Torrent, Iu Raïch, Ángel González, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 18, pp. 5927-5935
Open Access | Times Cited: 7
Cannabidiol and periodontal inflammatory disease: A critical assessment
P Jirásek, A Jusku, Vilı́m Šimánek, et al.
Biomedical Papers (2022) Vol. 166, Iss. 2, pp. 155-160
Open Access | Times Cited: 12
Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen/Glucose-Deprived Neurons
Jaume Lillo, Iu Raïch, Laura Silva, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9695-9695
Open Access | Times Cited: 11
Stereoisomers of cannabidiols and their pharmacological activities – A potentially novel direction for cannabinoids
Vajja Krishna Rao, Melissa M. Lewis‐Bakker, Ewa Wasilewski, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 117, pp. 118019-118019
Open Access | Times Cited: 2
Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators
Paula Morales, Chanté Muller, Nadine Jagerovic, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 10
Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules
Ayat Zagzoog, Ashley Cabecinha, Hanan Abramovici, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB2 Receptor via the Lipid Bilayer
Nil Casajuana‐Martin, Gemma Navarro, Ángel González, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 22, pp. 5771-5779
Open Access | Times Cited: 9
Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB2 receptor
Jara Bouma, Jeremy D. Broekhuis, Cas van der Horst, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115924-115924
Open Access | Times Cited: 5
The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors
Rafael Franco, Paula Morales, Gemma Navarro, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 8
Bridging the Binding Sites: Dualsteric Ligands for the Cannabinoid 2 Receptor (CB2R)
Anna Tutov, Sophie A. M. Steinmüller, Yesid A. Ramírez, et al.
Advanced Therapeutics (2023) Vol. 6, Iss. 4
Open Access | Times Cited: 4
Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging
Daniel Modemann, Andhika B. Mahardhika, Sabrina Yamoune, et al.
European Journal of Medicinal Chemistry (2022) Vol. 232, pp. 114138-114138
Closed Access | Times Cited: 6
Effect of Fatty Acid Amide Hydrolase Inhibitor URB597 on Orofacial Pain Perception in Rats
Marek Zubrzycki, Maria Zubrzycka, Grzegorz Wysiadecki, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4665-4665
Open Access | Times Cited: 6
Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits
Anthony S. Ferranti, Daniel J. Foster
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top